you are a relentless cheerleader and your posts are tiresome
you call it negativity I call it financial experience and logic
why don't you go on down the road
no one listens to your incessant pumping
I may buy at $2 post split
---D O D ? sure when?
---Sales of the NJ Tax credits are problematic- the buyer has to pay at least 75% of the value see the NJ Tax website - so they are not really worth that much to the buyer- and why haven't they been sold already if so valuable been hearing this for 9 months
--when they get a banker I'll believe in the IPO
--I know a company that got a grant from MJF only $100k
--where's the partnership for Elz
you guys always neglect to mention new capital
the are going to burn 1.5 mil per month--where is the $ going to come from
even if they get a grant or two it's usuasllly peanuts like a few hundred k.
so they have to raise at least 12 to 24 mil. minimum just to stay alive for 2 years.
they still don't have an investment banker
that means the current holders are going to be diluted big time
it's going to 2 or 3 bucks post split.
you know nothing
changing a cusip has nothing to do with short selling-
your broker will still show you short and you won't have to cover
looks like that's where jnj is heading
Not conv at 6 cents--read the 8k
.... The Series G Preferred Stock may also be converted into shares of common stock at the option of the Company if the Equity Conditions, as defined in the Certificate of Designation, are met. Upon conversion, the Company shall pay the holders of the Series G Preferred Stock being converted a conversion premium equal to the amount of dividends that such shares would have otherwise earned if they had been held through the maturity date, and issue to the Investor such number of shares of Common stock equal to $5,000 per share of Series G Preferred Stock (the “Face Value”) multiplied by the number of Series G Preferred Stock divided by the conversion rate of $0.06.
The conversion premium may be paid in cash or, at the Company’s option, additional shares of common stock. If the Company elects to pay the conversion premium amount in the form of common stock the number of shares to be issued shall be calculated by using 80% of the average of the lowest 5 individual daily volume weighted average prices during the measuring period, not to exceed 100% of the lowest sales prices on the last day of such period, less $0.005 per share of common stock.. Following an Event of Default, the number of shares to be issued shall be calculated by using 65% of the average of the lowest 5 individual daily volume weighted average prices during the measuring, less $0.005 per share of common stock not to exceed 70% of the lowest sales prices on the last day
ITS TOXIC shs conv at 80% of mkt not 6 cents
well the stock price action says it all. Whatever the relationship, the stroke study obviously isn't covered by the license / milestone agreement Market up, Biotechs up (look at CLDX) this is down.
why toxic convert.financing?
why don't they have a reputable investment banker?
Why don't they have a deal with big pharma?
not much here- that s why its 8 cents
I lost $$$ in the common. Sold yesterday and bought the bonds. Took the loss. BTW Buying the bonds doesn't trigger the wash sale rule.
HY funds are dumping highly levered oil co. bonds. SD's 8 3/4 % 5 yr. paper is trading at 66 down form 92 just 3 mos. ago. The bonds are still money good with a 19% ytm.
If the stock is worth anything going forward the bonds will trade at par. Even in a BK (doubtful) bondholders get paid before shareholders.
Why own the stock?
Management are nit wits. BMY bought Medarex and CLDX came out of Medarex. Sell to BMY.
Maybe we'll get 18 to 20. This team couldn't find their #$%$ with both hands.